Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Lamivudine
Drug ID BADD_D01242
Description A reverse transcriptase inhibitor and zalcitabine analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat Human Immunodeficiency Virus Type 1 (HIV-1) and hepatitis B (HBV).
Indications and Usage For the treatment of HIV infection and chronic hepatitis B (HBV).
Marketing Status approved; investigational
ATC Code J05AF05
DrugBank ID DB00709
KEGG ID D00353
MeSH ID D019259
PubChem ID 60825
TTD Drug ID D07TQV
NDC Product Code 65015-756; 49702-203; 60687-362; 53873-075; 49702-205; 69097-167; 42385-714; 52482-003; 70966-0036; 0173-0663; 65862-055; 60505-3252; 65862-026; 69097-166; 53873-073; 55773-0589; 68554-0043; 31722-001; 49702-204; 64380-710; 68554-0016; 31722-752; 31722-754; 50742-624; 60687-720; 64380-711; 68180-602; 53104-7677; 70159-001; 31722-753; 54838-566; 57237-274; 60429-354; 66993-478; 68180-603; 53104-7538; 65015-701; 67835-0017; 60505-3250; 0904-6583; 53873-074; 65862-577; 33342-001; 0173-0662; 60505-3251; 65862-259; 65862-025; 82245-0204; 33342-002; 50742-623; 60429-353
UNII 2T8Q726O95
Synonyms Lamivudine | 3TC | 2',3'-Dideoxy-3'-thiacytidine | 2',3' Dideoxy 3' thiacytidine | Epivir | Lamivudine, (2S-cis)-Isomer | BCH-189 | BCH 189 | BCH189 | GR-109714X | GR109714X
Chemical Information
Molecular Formula C8H11N3O3S
CAS Registry Number 134678-17-4
SMILES C1C(OC(S1)CO)N2C=CC(=NC2=O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Arthralgia15.01.02.001--
Ascites09.01.05.003; 07.07.01.001; 02.05.04.0020.001518%
Aspartate aminotransferase13.03.04.008--Not Available
Aspartate aminotransferase increased13.03.04.011--
Asthenia08.01.01.0010.009613%Not Available
Ataxia17.02.02.001; 08.01.02.0040.001012%
Auricular swelling04.01.01.002--Not Available
Back pain15.03.04.005--
Blood bilirubin13.03.04.015--Not Available
Blood creatine phosphokinase increased13.04.01.001--
Blood triglycerides increased13.12.03.001--Not Available
Body temperature increased13.15.01.001--Not Available
Bone disorder15.02.04.004--Not Available
Breast enlargement21.05.04.001--Not Available
Bronchitis22.07.01.001; 11.01.09.001--
Cardiomyopathy02.04.01.001--Not Available
Cardiovascular disorder02.11.01.010; 24.03.02.0090.002024%Not Available
Carotid artery stenosis24.04.06.001; 17.08.02.0010.002024%Not Available
Cerebellar syndrome17.02.02.0020.001012%Not Available
Chest pain22.12.02.003; 08.01.08.002; 02.02.02.011--Not Available
Chills08.01.09.001; 15.05.03.016--
Cholecystitis acute09.03.01.0030.001012%Not Available
Chronic hepatitis11.07.01.009; 09.01.07.021--Not Available
Circulatory collapse24.06.02.0010.001012%Not Available
Completed suicide19.12.01.001; 08.04.01.010--Not Available
Confusional state19.13.01.001; 17.02.03.005--
Constipation07.02.02.001--
Cough22.02.03.001--
Deafness04.02.01.001--Not Available
Death08.04.01.001--
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 13 Pages